Alnylam Pharmaceuticals Reports Fourth Quarter and Year End 2005 Financial Results.

Extract

---

Alnylam Pharmaceuticals Reports Fourth Quarter and Year End 2005 Financial Results.

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY):

--Company Enters Clinical Stage and Forms Significant Pharmaceutical Alliances

--Maintains Leadership Position for RNAi Therapeutics in Science, Product Pipeline, Intellectual Property, and Business Execution

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter and year ended December 31, 2005, guidance and goals for 2006, and company highlights.

"2005 was a transformational year for Alnylam," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. "Of significance, we transitioned to a clinical-stage company, formed collaborations with Novartis and Medtronic to discover and develop RNAi therapeutics, continued to strengthen and leverage our unparalleled intellectual property position in RNAi, and maintained a strong financial profile. As is evident by the goals we have set for ourselves, we believe that 2006 will be an equally important year for Alnylam and the field of RNAi."

Cash, Cash Equivalents, and Marketable Securities

At December 31, 2005, Alnylam had cash, cash equivalents, and marketable securities (cash) of $80.0 million, compared to $24.8 million at September 30, 2005 and $46.0 million at December 31, 2004. This cash balance does not include approximately $62.3 million of net proceeds from the company's public offering of approximately 5.1 million shares of ...

See the full content of this document

---